The clinical efficacy of hydroxyfasudil in senile heart failure caused by coronary heart disease
10.3969/j.issn.1006-5725.2015.14.043
- VernacularTitle:盐酸法舒地尔对老年冠心病心力衰竭的临床疗效
- Author:
Yugang YIN
;
Bin YAN
;
Lei LV
- Publication Type:Journal Article
- Keywords:
Coronary heart disease;
Hydroxyfasudil;
Heart failure;
Rho kinase;
Tei index
- From:
The Journal of Practical Medicine
2015;31(14):2376-2378
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of hydroxyfasudil in senile heart failure caused by coronary heart disease (CHD). Methods 110 Patients with heart failure caused by CHD were randomly divided into two groups. 55 patients in control group were given conventional treatment, whereas the remaining patients were assigned into hydroxyfasudil group in the base of conventional treatment. After 6 months, we observed and compared the changes in cardiac function of the two groups. Results The effective rate of treatment group was 96.36% and the control group was 85.45%. There was statistical difference between the two groups (P < 0.05). Then we compared the degree of improvement of left ventricular diastolic function using ultrasonic cardiogram and Tei index. Left ventricular ejection fraction of treatment group improved significantly but biochemical indicators of two groups had no statistical difference. Conclusion In patients with heart failure caused by CHD, supplementation of hydroxyfasudil based on conventional therapy could improve diastolic function , potentiate left ventricular remodeling and enhance the life quality. Furthermore, it′s more sensitivity and reasonable to assess cardiac function using Tei index as compared with using ultrasonic cardiogram.
